1.48
+0.08(+5.71%)
Currency In USD
| Previous Close | 1.4 |
| Open | 1.42 |
| Day High | 1.49 |
| Day Low | 1.4 |
| 52-Week High | 1.84 |
| 52-Week Low | 0.81 |
| Volume | 182,519 |
| Average Volume | 1.11M |
| Market Cap | 78.43M |
| PE | -0.95 |
| EPS | -1.56 |
| Moving Average 50 Days | 1.41 |
| Moving Average 200 Days | 1.26 |
| Change | 0.08 |
If you invested $1000 in PMV Pharmaceuticals, Inc. (PMVP) since IPO date, it would be worth $39.46 as of September 29, 2025 at a share price of $1.48. Whereas If you bought $1000 worth of PMV Pharmaceuticals, Inc. (PMVP) shares 3 years ago, it would be worth $124.27 as of September 29, 2025 at a share price of $1.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
GlobeNewswire Inc.
Sep 10, 2025 11:00 AM GMT
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR)
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 11, 2025 1:00 PM GMT
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 07, 2024 1:00 PM GMT
Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; i